




Roche Satellite Symposium
Presented for attendees of the 1st Czech
and Slovak Transplant Congress

ABSTRACT BOOK

Novel Strategies
in Transplant
Medicine

16. 11. 2006
10.00 - 12.00





Dr. Henrik Ekberg

Dr. Henrik Ekberg is Senior Transplant Surgeon at the University Hospital in Malmö, Sweden, and Professor of Transplant Surgery at Lund University. His main research interests concern immunosuppressive treatment, clinically as well as experimentally. He received his MD degree in 1977 and his board certification in General Surgery in 1985. He presented his PhD thesis in 1986 and after two years of research in the field of transplantation at the University of Sydney in Australia, focusing on pancreas transplantation, he was appointed to his present clinical position and Associate Professor. In 2001, Dr. Ekberg was appointed Professor of Transplant Surgery at Lund University. In the last 15 years, he has had an active role in a large number of pivotal multicenter trials on immunosuppression in renal transplantation. At present time, Dr. Ekberg is sponsor and chairman of the steering committee of the ongoing multicenter international Symphony study. Dr. Ekberg is Associate Editor of the American Journal of Transplantation and member of the editorial board of Transplantation and that of Transplant International. He is also Councillor for The Transplantation Society (TTS) and vice-president of the European Society of Organ Transplantation (ESOT). Dr. Ekberg is a frequently invited lecturer and has published more than 150 original articles and reviews in the field of transplantation.

Symphony – Balancing efficacy and toxicities in renal transplant patients

Henrik Ekberg, MD, PhD
Lund University, Malmö, Sweden

Abstract

The CAESAR study showed that the use of low-dose cyclosporine A (CsA) in combination with daclizumab, mycophenolate mofetil (MMF, CellCept®) and corticosteroids is safe and effective. However, complete CsA withdrawal at 4-6 months after transplantation was associated with an increased risk of acute rejection¹. Thus, a balance needs to be found between reducing toxicity and maintaining efficacy.

The main objective of the Symphony trial was to determine whether low doses of CNIs or sirolimus (SRL) in conjunction with MMF and daclizumab may be beneficial in comparison with standard-dose CsA-based immunosuppression. The study aimed at demonstrating improved renal function while at the same time providing an acceptable rate of acute rejection and a favourable safety profile.

Symphony is the largest ever prospective study in de novo renal transplant patients. In the Symphony study, 1645 adult patients were randomised to receive one of the following treatments: standard-dose CsA (target trough level 150-300 ng/ml for 3 months, 100-200 ng/ml thereafter), 1g bid MMF and corticosteroids (Group A), or daclizumab induction (2mg/kg followed by 4 x 1mg/kg every 2 weeks), 1 g bid MMF and corticosteroids in combination with either low-dose CsA (50-100 ng/ml; Group B), low-dose TAC (3-7 ng/ml; Group C) or low-dose SRL (4-8 ng/ml; Group D).

Differences in glomerular filtration rate (GFR) and biopsy-proven acute rejection (BPAR) were statistically significant among the 4 groups ($p < 0.0001$). The low-

dose TAC group was significantly superior to all other groups with respect to mean calculated GFR, as measured by Cockcroft-Gault (65.6 ml/min compared with 56.7-59.7 ml/min) at 12 months. The lowest incidence of BPAR at 12 months (12% compared with 24-37%) was also observed in the low-dose TAC group. In addition, 12-month graft survival was significantly better in this treatment group than in the standard-dose CsA (94% vs 89%, $p = 0.0108$) and the low-dose SRL groups (94% vs 89%, $p = 0.0115$). No significant differences in patient survival were observed between the 4 treatment groups. The safety profile was similar between the treatment groups with no significant differences in most of the parameters measured. In patients receiving low-dose TAC, significantly higher incidences of diarrhoea (26% vs 15-22%, $p = 0.0003$) and diabetes mellitus (11.5% vs 5.7-8.6%) were observed, whereas in patients receiving low-dose SRL a significantly higher incidence of lymphoceles (12.9% vs 3.6-6.0%, $p < 0.0001$) was detected.

The Symphony study proves that MMF with low-dose TAC maximises the function and longevity of the organ. This combination protects the patient by providing the best balance between efficacy and toxicity available to date.

References

- ¹Ekberg H. Transplantation 2004; 78 (Supl.):458-9 (Abs. P734).
- ²Ekberg H. World Transplant Congress 2006, Boston, USA.





Bart D. Maes, MD, PhD

Bart Maes is currently Nephrologist at the Heilig Hartziekenhuis of Roeselare, Belgium. His research interests include immunosuppressive therapy in transplantation and glomerulonephritis, metabolic and gastrointestinal disorders in transplantation, and hepatic and gastrointestinal metabolism of immunosuppressive drugs (CYP3A4 and P-glycoprotein system). His articles on these subjects appear in a variety of peer-reviewed journals. Dr. Maes received his MD and PhD (gastric motility) from the Catholic University of Leuven.

Severe diarrhea in renal transplant patients: Results of the DIDACT Study

Bart D. Maes, MD, PhD

Abstract

Diarrhea is common in transplant recipients. While the majority of cases are mild and transient, some are severe and prolonged, which can threaten graft survival through dehydration. While it is known that some immunosuppressive agents can elicit diarrhea, there does not appear to be any consensus on the role that other non-immunosuppressive causes can play in transplant patients. The aim of the DIDACT-study - an open, non-randomized, multicenter study - was to identify non-immunosuppressive factors involved in severe diarrhea in renal transplant patients. Patients (n=108) with severe diarrhea (≥ 3 stools/day for ≥ 7 days) were enrolled from 16 Belgian transplant centers. Patients were diagnosed according to an agreed flowchart that consisted of identification of possible infections, followed by changes in empirical and immunosuppressive treatment. Approximately 50% of patients experienced resolution of severe diarrhea following treatment for infections, dietary problems or diarrhea-causing concomitant medications. In conclusion, a large proportion of the severe diarrhea observed in renal transplant recipients is not associated with immunosuppressive therapy and can be treated through anti-infectives, changes to concomitant medication and other empirical treatments. Correct diagnosis of the cause of severe diarrhea in such patients should help to protect graft survival in transplant recipients.



Tomas Reischig, MD

Born on March 4, 1972 (Pilsen)

Education

- 9/90 – 6/96 (Degree Doctor of Medicine in 6/96) - School of Medicine in Pilsen, Charles University (Honored by Dean's Award for the study results)
- 4/99 1st Degree in Internal Medicine (postgraduate)
- 4/03 2nd Degree in Nephrology (postgraduate)

Professional Experience

- 9/96–up to now Charles University Teaching Hospital, Department of Internal Medicine I, Department of Nephrology, Transplant Centre. During the period 1996 – 1997 I was working on nephrology department (inpatient care) and hemodialysis centre. Since 1998 I have been working as a transplant nephrologist. I was designated as a head of Division of nephrology in September 2006.

Research

- At the beginning my research activity was focused on anemia in end-stage kidney patients. Later on I started with studies on the impact of infectious complications after kidney transplantation, particularly cytomegalovirus infection. I presented our research data at major transplant meetings such as ATC, ESOT and TTS congresses. Results of our clinical studies were published in prestigious transplant journals. In 2006 I was awarded by The Czech Transplantation Society for the publication in the Transplantation journal.

Full Text Publications in Journals with Impact Factor

- Reischig T., Bouda M., Opatrný K. Jr., Těšínský P., Čepelák M., Duras P, Třeška V. Management of acute necrotizing pancreatitis after renal transplantation. *Transplant Proc.* 2001 Feb-Mar;33(1-2):2020-3.
- Opatrný K Jr, Reischig T, Vienken J, Eiselt J, Vit L, Opatrná S, Sefrna F, Racek J, Brown GS. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis. *Artif Organs* 2002 Feb;26(2):181-8.
- Reischig T., Opatrný K. Jr., Bouda M., Treska V., Jindra P., Svecova M. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus (CMV) disease after renal transplantation. *Transpl Int* 2002, 15: 615-622.
- Třeška V., Racek J., Kuntscher V., Hasman D., Kobr J., Molacek J., Trefil O., Hes O., Reischig T. Plasma and Tissue Levels of Free Oxygen Radicals in Recipients of Kidneys From Non-Heart-Beating Donors: Does Recipient Pretreatment With Antioxidant Drugs Make Sense? An Experimental Study in Pigs. *Transplant Proc* 2002, 34: 3060-3064.
- Reischig T., Jindra P., Mares J., Cechura M., Svecova M, Hes O., Opatrný K. Jr., Treska V. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. *Transplantation* 2005, 79: 317-324.
- Reischig T., Opatrný K. Jr., Treska V, Mares J., Jindra P., Svecova M. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. *Kidney Blood Press Res* 2005, 28: 218-225.
- Reischig T., Jindra P., Svecova M., Kormunda S., Opatrný K. Jr, Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. *J Clin Virol* 2006, 36: 146-151.

August 31, 2006

Tomáš Reischig, MD

